Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

California Govenor Outlines Cuts To Address State's Budget Deficit Problems
California Gov. Arnold Schwarzenegger (R) outlined two budget proposals to address the state"s budget problems, and both plans would affect health care, the Los Angeles Times reports. The first proposal addresses the situation if California voters approve a set of special ballot measures intended to provide funds for fiscal year 2009-2010. The state would still face a $15.4 billion budget deficit even if voters approve the measures, and the second proposal addresses that scenario (Rothfeld, Los Angeles Times, 5/15). The governor proposed $750 million in cuts to Medi-Cal, the state"s Medicaid program, that would reduce eligibility and provider rates. The state would need to seek a federal waiver to implement the cuts. The governor also proposed eliminating eligibility for non-emergency Medi-Cal benefits for documented immigrants (Colliver, San Francisco Chronicle, 5/15). Spending for centers that provide services to people with developmental disabilities would be cut by $234 million (Zapler, San Jose Mercury News, 5/14).If voters do not approve three ballot measures, Schwarzenegger outlined $800 million in additional cuts to health and human services programs, including a proposal to eliminate Healthy Families coverage for about 225,000 children. Healthy Families is California"s CHIP (Yi et al., San Francisco Chronicle, 5/15).
buy viagra
Needs Of Bottle Feeding Mums Neglected
The needs of mothers who bottle feed are being neglected, potentially risking the health of their babies, suggests research published ahead of print in the Archives of Disease in Childhood.
plan for health
News of the day
$1.8 Million To Improve Vaccine Strategies For P. Carinii Pneumonia Awarded To LSUHSC's Kolls
Jay K. Kolls, MD, Professor and Chairman of Genetics at LSU Health Sciences Center New Orleans School of Medicine, has been awarded $1.8 million over five years by the National Heart, Lung and Blood Institute of the National Institutes of Health to study whether antibodies that recognize carbohydrate (sugars) and proteins on the surface of the fungus that causes Pneumocystis carinii pneumonia (PCP) can be used to prevent the infection.
Sexual Health

FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System

Boston Scientific Corporation (NYSE: BSX) announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM) Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month. "The rapid adoption of the TAXUS Express Atom Stent has confirmed the need for this type of stenting option in the treatment of small-vessel coronary artery disease," said Mark Turco, M.D., F.A.C.C., F.S.C.A.I., Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "The TAXUS Liberte Atom Stent provides clear design and deliverability advantages. Additionally, in the TAXUS Atlas Small Vessel clinical trial, the TAXUS Liberte Atom Stent yielded a two-year target lesion revascularization rate that was 60 percent less than the TAXUS Express Atom Stent. I am pleased to be able to offer this option to my patients." Data from numerous clinical studies have shown that an estimated 10 percent of patients undergoing percutaneous coronary interventions have small vessels (Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document. Boston Scientific Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009